Odyssey Therapeutics Files for IPO

Dow Jones04-18

By Josh Beckerman

Odyssey Therapeutics filed for an initial public offering.

The move follows a confidential filing in February and a June 2025 withdrawal of a prior IPO plan.

The Boston-based biopharmaceutical company said in September that it raised $213 million of Series D financing. In addition to participation from all existing investors, new investors included Affinity Asset Advisors, Dimension Capital, Jeito Capital, Lightspeed Ventures, TPG Life Sciences Innovations, and Wedbush Healthcare Partners, the company said at the time.

SR One Capital Management owns a 10.6% stake, according to the filing. Other top shareholders include OrbiMed and Fidelity.

Odyssey is seeking a Nasdaq Capital Market listing under symbol ODTX.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

April 17, 2026 17:17 ET (21:17 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2628278249?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-18 05:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2628278249","market":"nz","top_or_hot":-1,"title":"Odyssey Therapeutics Files for IPO","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Odyssey <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> filed for an initial public offering. \n</p>\n<p>\n  The move follows a confidential filing in February and a June 2025 withdrawal of a prior IPO plan. \n</p>\n<p>\n  The Boston-based biopharmaceutical company said in September that it raised $213 million of Series D financing. In addition to participation from all existing investors, new investors included Affinity Asset Advisors, Dimension Capital, Jeito Capital, Lightspeed Ventures, TPG Life Sciences Innovations, and Wedbush Healthcare Partners, the company said at the time. \n</p>\n<p>\n  SR One Capital Management owns a 10.6% stake, according to the filing. Other top shareholders include OrbiMed and Fidelity. \n</p>\n<p>\n  Odyssey is seeking a Nasdaq Capital Market listing under symbol ODTX. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 17, 2026 17:17 ET (21:17 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Odyssey Therapeutics Files for IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOdyssey Therapeutics Files for IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-18 05:17</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Odyssey <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> filed for an initial public offering. \n</p>\n<p>\n  The move follows a confidential filing in February and a June 2025 withdrawal of a prior IPO plan. \n</p>\n<p>\n  The Boston-based biopharmaceutical company said in September that it raised $213 million of Series D financing. In addition to participation from all existing investors, new investors included Affinity Asset Advisors, Dimension Capital, Jeito Capital, Lightspeed Ventures, TPG Life Sciences Innovations, and Wedbush Healthcare Partners, the company said at the time. \n</p>\n<p>\n  SR One Capital Management owns a 10.6% stake, according to the filing. Other top shareholders include OrbiMed and Fidelity. \n</p>\n<p>\n  Odyssey is seeking a Nasdaq Capital Market listing under symbol ODTX. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 17, 2026 17:17 ET (21:17 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2628278249","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2628278249","pubTimestamp":1776460620,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Odyssey Therapeutics filed for an initial public offering.The move follows a confidential filing in February and a June 2025 withdrawal of a prior IPO plan.The Boston-based biopharmaceutical company said in September that it raised $213 million of Series D financing. In addition to participation from all existing investors, new investors included Affinity Asset Advisors, Dimension Capital, Jeito Capital, Lightspeed Ventures, TPG Life Sciences Innovations, and Wedbush Healthcare Partners, the company said at the time.SR One Capital Management owns a 10.6% stake, according to the filing. Other top shareholders include OrbiMed and Fidelity.Odyssey is seeking a Nasdaq Capital Market listing under symbol ODTX.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","IPOS":"Renaissance International IPO ETF","BK4139":"生物科技","SPCX":"SPAC and New Issue ETF","BK4135":"资产管理与托管银行","BK4007":"制药","TPG":"TPG, Inc.","BK4539":"次新股"},"translate_title":"奥德赛治疗公司申请IPO","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"IPOS":1.5,"TPG":0.9,"SPCX":1.5},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Odyssey Therapeutics filed for an initial public offering. \n\n\n  The move follows a confidential filing in February and a June 2025 withdrawal of a prior IPO plan. \n\n\n  The Boston-based biopharmaceutical company said in September that it raised $213 million of Series D financing. In addition to participation from all existing investors, new investors included Affinity Asset Advisors, Dimension Capital, Jeito Capital, Lightspeed Ventures, TPG Life Sciences Innovations, and Wedbush Healthcare Partners, the company said at the time. \n\n\n  SR One Capital Management owns a 10.6% stake, according to the filing. Other top shareholders include OrbiMed and Fidelity. \n\n\n  Odyssey is seeking a Nasdaq Capital Market listing under symbol ODTX. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 17, 2026 17:17 ET (21:17 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2628278249","isCrawlerRequest":true}